Finoriq research workspace
SpyGlass Pharma, Inc. (SGP) SEC Filings & Filing Highlights
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug. Review SGP SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
- Company
- SpyGlass Pharma, Inc. (SGP)
- Ticker
- SGP
- Market Cap
- $667.8M
- Latest Price
- $19.98
- Industry
- Medical Devices
SpyGlass Pharma, Inc. (SGP) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for SpyGlass Pharma, Inc. (SGP).
| Event | Form | Date |
|---|---|---|
| SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | 8-K2.02 | 2026-05-14 |
| SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Upd...SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update | 8-K2.02 | 2026-03-26 |
| SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative...SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 8-K8.01 | 2026-03-09 |
| On January 16, 2026, SpyGlass Pharma, Inc. (the “Company”) filed a Registration Statement on Fo...On January 16, 2026, SpyGlass Pharma, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292779) with the Securi... | 8-K5.02 | 2026-02-13 |
| SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underw...SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares | 8-K7.01 | 2026-02-09 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.